Septerna Doses First Participants in SEP-479 Clinical Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy SEPN?
Septerna announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose and multiple-ascending dose clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEPN
Wall Street analysts forecast SEPN stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.670
Low
25.00
Averages
33.14
High
43.00
Current: 24.670
Low
25.00
Averages
33.14
High
43.00
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Amazon Launches GLP-1 Weight Loss Program
- Increased Market Competition: Amazon's launch of the GLP-1 management program through One Medical integrates obesity treatment with routine care, likely pressuring shares of companies like Hims & Hers Health and Viking Therapeutics, which fell following the announcement.
- Transparent Pricing: The pricing for GLP-1 medications will start as low as $25 per month for insured patients, aiming to attract more customers by simplifying access to medications and enhancing market share.
- Convenient Drug Delivery: Amazon plans to expand same-day drug delivery to 4,500 cities by the end of 2026, leveraging its robust logistics network to improve customer experience and gain an edge in the competitive weight loss drug market.
- Diverse Treatment Options: Through Amazon Pharmacy, patients can access various GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, further driving the company's expansion into the healthcare sector.
See More
Septerna, Inc. Q4 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q4 GAAP EPS of -$0.24, beating expectations by $0.02, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company achieved Q4 revenue of $24.1 million, soaring 11950% year-over-year and exceeding market expectations by $8.54 million, demonstrating robust demand and rapid growth potential for its products or services.
- Positive Future Outlook: With the Phase 1 readout of SEP-631 approaching, Septerna anticipates a key market driver in 2026, which could further boost the company's stock price and market recognition.
- Quant Rating Improvement: Seeking Alpha's quant rating on Septerna, Inc. reflects growing market confidence in its future performance, indicating investor recognition of the company's strategic direction and growth potential.
See More
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
- Clinical Trial Success: Septerna's SEP-631 demonstrated good tolerability and pharmacokinetic characteristics in its Phase 1 clinical trial for mast cell-driven diseases, supporting once-daily oral dosing with a half-life of 24 hours, indicating its potential for treating chronic spontaneous urticaria and other conditions.
- Efficacy Validation: At a dose of 10 mg, SEP-631 showed significant suppression of skin wheal formation, with nearly complete inhibition observed at 90 mg and 200 mg doses, demonstrating a dose-dependent response that further validates its application in mast cell-driven diseases.
- Follow-Up Research Plans: Based on the positive Phase 1 results, Septerna plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2023, aiming to evaluate the efficacy of SEP-631 in adult patients who remain symptomatic despite treatment with second-generation antihistamines.
- Multiple Indication Exploration: In addition to chronic spontaneous urticaria, Septerna is also exploring the efficacy of SEP-631 in other mast cell-driven diseases, including atopic dermatitis, interstitial cystitis, migraine, and asthma, showcasing its broad market potential.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Amazon Launches GLP-1 Management Program to Transform Weight Loss Treatment
- Market Expansion: Amazon is launching a new GLP-1 management program through its primary care arm, Amazon One Medical, aiming to integrate obesity treatment into routine care, which is expected to significantly enhance patient adherence to long-term weight management.
- Transparent Pricing: The program offers insured pricing starting as low as $25 per month, while cash-paying patients will find oral medications starting at $149 per month and injectable treatments like Wegovy at $299, positioning Amazon competitively in the market despite similar pricing.
- Convenient Services: Amazon Pharmacy will provide on-demand prescription renewals, starting at $29 for message consultations and $49 for video care, which is likely to attract more customers and enhance loyalty and market share.
- Logistical Advantage: Amazon plans to expand its same-day drug delivery service to 4,500 cities by the end of 2026, leveraging its robust logistics network and consumer reach to solidify its position within the healthcare system.
See More
Amazon Launches GLP-1 Weight Loss Program
- Increased Market Competition: Amazon's launch of the GLP-1 management program through One Medical integrates obesity treatment with routine care, likely pressuring shares of companies like Hims & Hers Health and Viking Therapeutics, which fell following the announcement.
- Transparent Pricing: The pricing for GLP-1 medications will start as low as $25 per month for insured patients, aiming to attract more customers by simplifying access to medications and enhancing market share.
- Convenient Drug Delivery: Amazon plans to expand same-day drug delivery to 4,500 cities by the end of 2026, leveraging its robust logistics network to improve customer experience and gain an edge in the competitive weight loss drug market.
- Diverse Treatment Options: Through Amazon Pharmacy, patients can access various GLP-1 medications, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, further driving the company's expansion into the healthcare sector.
See More
Septerna, Inc. Q4 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q4 GAAP EPS of -$0.24, beating expectations by $0.02, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company achieved Q4 revenue of $24.1 million, soaring 11950% year-over-year and exceeding market expectations by $8.54 million, demonstrating robust demand and rapid growth potential for its products or services.
- Positive Future Outlook: With the Phase 1 readout of SEP-631 approaching, Septerna anticipates a key market driver in 2026, which could further boost the company's stock price and market recognition.
- Quant Rating Improvement: Seeking Alpha's quant rating on Septerna, Inc. reflects growing market confidence in its future performance, indicating investor recognition of the company's strategic direction and growth potential.
See More
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
- Clinical Trial Success: Septerna's SEP-631 demonstrated good tolerability and pharmacokinetic characteristics in its Phase 1 clinical trial for mast cell-driven diseases, supporting once-daily oral dosing with a half-life of 24 hours, indicating its potential for treating chronic spontaneous urticaria and other conditions.
- Efficacy Validation: At a dose of 10 mg, SEP-631 showed significant suppression of skin wheal formation, with nearly complete inhibition observed at 90 mg and 200 mg doses, demonstrating a dose-dependent response that further validates its application in mast cell-driven diseases.
- Follow-Up Research Plans: Based on the positive Phase 1 results, Septerna plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2023, aiming to evaluate the efficacy of SEP-631 in adult patients who remain symptomatic despite treatment with second-generation antihistamines.
- Multiple Indication Exploration: In addition to chronic spontaneous urticaria, Septerna is also exploring the efficacy of SEP-631 in other mast cell-driven diseases, including atopic dermatitis, interstitial cystitis, migraine, and asthma, showcasing its broad market potential.
See More
